Date | Title | Description | |
---|---|---|---|
22 Feb 2022 | On buy-back programmes | ROVI reports the end of the share buy-back programme, effective as of 3 November 2021, and the launching of a new share buy-back programme, effective as of 23 February 2022. | Download |
16 Feb 2022 | On business and financial situation | Moderna and ROVI announced that they expand their long-term collaboration for the manufacture of mRNA medicines over the next ten years | Download |
03 Nov 2021 | On buy-back programmes | The Company reports the commencement, effective as of today, 3 November 2021, of a share buyback program. | Download |
16 Jul 2021 | On Corporate Governance | ROVI announces the appointment of Juan López-Belmonte Encina as Chairman of the Company | Download |
22 Jun 2021 | On significant placements in financial instruments | Bestinver announces the beginning of an accelerated book build process of up to a 3% of the share capital of Laboratorios Rovi, S.A. | Download |
Pages
Date | Title | Description | |
---|---|---|---|
16 Jun 2022 | Other relevant information | The Company has agreed to execute the capital reduction approved by the 2022 Ordinary General Meeting to amortize the shares acquired in the framework of the own shares repurchase programs | Download |
14 Jun 2022 | Announcement of general shareholders’ meeting | ROVI releases the information related to its General Shareholders Meeting | Download |
11 May 2022 | On business and financial situation | The Company releases the first quarter 2022 financial results presentation | Download |
11 May 2022 | Announcement of general shareholders’ meeting | Rovi releases the information related to its 2022 General Shareholders Meeting | Download |
11 May 2022 | On Corporate Governance | The Company informs about the appointment of a new member in its Board of Directors | Download |